Dr. Jonasch on the Target Population for Treatement with Belzutifan in RCC
In Partnership With:
Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the best patient population when treating with belzutifan (Welireg) in clear cell renal cell carcinoma (RCC).
The phase 1 LITESPARK-001 trial (NCT02974738) is evaluating belzutifan, a novel hypoxia-inducible factor-2α (HIF-2α) inhibitor, to determine the maximum tolerated dose and the recommended phase 2 dose in patients with advanced solid tumors, including clear cell RCC.
The trial accrued patients at multiple centers, and patients in the RCC cohort needed to have locally advanced or metastatic solid sporadic clear cell RCC and have received at least 1 prior treatment with a standard-of-care regimen for advanced RCC, Jonasch explains.
Of the 55 patients enrolled in the RCC cohort, patients received a median of 3 prior lines of therapy, Jonasch continues.
